COVID-19 genomic susceptibility: Definition of ACE2 variants relevant to human infection with SARS-CoV-2 in the context of ACMG/AMP Guidance

Claire L Shovlin, Marcela P. Vizcaychipi
doi: https://doi.org/10.1101/2020.05.12.20098160

Article Information

doi 
https://doi.org/10.1101/2020.05.12.20098160
History 
  • June 4, 2020.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Claire L Shovlin, PhD FRCP1,2,* and
  2. Marcela P. Vizcaychipi, MD PhD3,4
  1. 1NHLI Vascular Science, Imperial College London, UK
  2. 2Respiratory Medicine, Imperial College Healthcare NHS Trust, London UK
  3. 3Anaesthesia and Intensive Care, Chelsea & Westminster NHS Foundation Trust, London, UK
  4. 4Surgery and Cancer, Imperial College London, UK
  1. ↵*Corresponding author
    Claire L. Shovlin, PhD FRCP. Professor of Practice (Clinical and Molecular Medicine), NHLI Vascular Science, Imperial Centre for Translational and Experimental Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK. email c.shovlin{at}imperial.ac.uk
Back to top
Posted June 04, 2020.
Download PDF
Data/Code
Email
COVID-19 genomic susceptibility: Definition of ACE2 variants relevant to human infection with SARS-CoV-2 in the context of ACMG/AMP Guidance
Claire L Shovlin, Marcela P. Vizcaychipi
medRxiv 2020.05.12.20098160; doi: https://doi.org/10.1101/2020.05.12.20098160
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area